ELICIO THERAPEUTICS INC (ELTX) Stock News

USA - Nasdaq - NASDAQ:ELTX - US28657F1030 - Common Stock

9.36 USD

+0.2 (+2.18%)

Last: 11/28/2025, 8:25:46 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ELTX Latest News, Press Relases and Analysis

All

Press Releases

10 days ago - By: Elicio Therapeutics Inc.

Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer

10 days ago - By: Elicio Therapeutics Inc.

Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer

16 days ago - By: Elicio Therapeutics Inc.

Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

16 days ago - By: Elicio Therapeutics Inc.

Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

4 months ago - By: The Motley Fool

Elicio (ELTX) Q2 Loss Beats Estimates

22 days ago - By: Elicio Therapeutics Inc.

Elicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P and New ELI-004 Preclinical Data at SITC

22 days ago - By: Elicio Therapeutics Inc.

Elicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P and New ELI-004 Preclinical Data at SITC

a month ago - By: Elicio Therapeutics Inc.

Elicio Therapeutics to Present Clinical and Preclinical Data at the SITC 2025 Annual Meeting

a month ago - By: Elicio Therapeutics Inc.

Elicio Therapeutics Reports Robust T cell Responses Across Diverse HLA backgrounds in Ongoing Phase 2 AMPLIFY-7P Trial

2 months ago - By: Elicio Therapeutics Inc.

Elicio Therapeutics Announces Investigator-Initiated Phase 1 Trial to be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma

2 months ago - By: Elicio Therapeutics Inc.

Elicio Therapeutics Announces Investigator-Initiated Phase 1 Trial to be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma

2 months ago - By: Elicio Therapeutics Inc.

Elicio Therapeutics Reports Inducement Grants

2 months ago - By: Elicio Therapeutics Inc.

Elicio Therapeutics Reports Inducement Grants

2 months ago - By: Elicio Therapeutics Inc.

Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial

2 months ago - By: Elicio Therapeutics Inc.

Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial

4 months ago - By: Elicio Therapeutics Inc.

Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant-Stage Patients

4 months ago - By: Elicio Therapeutics Inc.

Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant-Stage Patients

4 months ago - By: Elicio Therapeutics Inc.

Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

4 months ago - By: Elicio Therapeutics Inc.

Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

4 months ago - By: Elicio Therapeutics Inc.

Elicio Therapeutics Announces Positive Recommendation by IDMC to Continue ELI-002 7P Randomized Phase 2 Study in Pancreatic Cancer Without Modifications to Final Analysis

4 months ago - By: Benzinga - Mentions: ALGN DYAI MDXG HCTI ...

12 Health Care Stocks Moving In Wednesday's After-Market Session

4 months ago - By: Yahoo Finance - Mentions: AUTL

Unlocking Oncology’s Future: 3 Trending Cancer Biotech Stocks with ‘Strong Buy’ Ratings

6 months ago - By: Elicio Therapeutics Inc.

Elicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Discuss AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer

6 months ago - By: Elicio Therapeutics Inc.

Elicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Discuss AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer

6 months ago - By: Elicio Therapeutics Inc.

Elicio Therapeutics Secures $10 Million in Financing

6 months ago - By: Elicio Therapeutics Inc.

Elicio Therapeutics Secures $10 Million in Financing

7 months ago - By: Elicio Therapeutics Inc.

Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates

7 months ago - By: Elicio Therapeutics Inc.

Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates

7 months ago - By: Zacks Investment Research

Here's Why Elicio Therapeutics (ELTX) Could be Great Choice for a Bottom Fisher

8 months ago - By: Elicio Therapeutics Inc.

Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New Hires

8 months ago - By: Elicio Therapeutics Inc.

Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New Hires

8 months ago - By: Yahoo Finance - Mentions: GME NKE LLY NVO

Why GameStop Stock Popped 11% Friday as Stock Indexes Fell

8 months ago - By: Benzinga - Mentions: CORT CTXR RSLS YCBD ...

12 Health Care Stocks Moving In Tuesday's Intraday Session

8 months ago - By: Elicio Therapeutics Inc.

Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates

8 months ago - By: Elicio Therapeutics Inc.

Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates

8 months ago - By: Elicio Therapeutics Inc.

Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer

10 months ago - By: Elicio Therapeutics Inc.

Elicio Therapeutics Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

10 months ago - By: Elicio Therapeutics Inc.

Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy